|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012854,
umls-concept:C0017262,
umls-concept:C0023779,
umls-concept:C0024109,
umls-concept:C0025914,
umls-concept:C0026809,
umls-concept:C0205360,
umls-concept:C0524527,
umls-concept:C1112870,
umls-concept:C1704241,
umls-concept:C1998497,
umls-concept:C2003864
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-7-17
|
|
pubmed:abstractText |
Advances in gene therapy vectors and techniques hold promise for treatment of many inherited and acquired diseases. For lung indications, especially those involving the epithelium, delivery of the gene therapy vehicle ideally will involve the use of an aerosol. Aerosol delivery of transgenes using cationic lipids is currently limited by the ability to generate highly concentrated formulations of lipid:DNA complexes that are stable and retain their activity following aerosolization. We have examined many of the variables inherent in aerosolizing cationic lipid gene delivery vehicles and have devised a new formulation that incorporates small amounts of a polyethylene glycol-containing lipid. This formulation has allowed the preparation of concentrated dispersions of cationic lipid:plasmid DNA (pDNA) complexes (> 20 mM pDNA) at approximately 10-fold higher concentrations than previously reported. Most of the pDNA in these formulations was bound to the lipid component and thereby protected from nebulizer-induced shearing; the pDNA also maintained full biological activity both in vitro and in vivo. This new formulation thus represents a significant improvement over current methods to prepare concentrated, active cationic lipid gene delivery vectors, and provides a new tool with which to test gene transfer to the lung.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1043-0342
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
765-73
|
|
pubmed:dateRevised |
2006-5-1
|
|
pubmed:meshHeading |
pubmed-meshheading:9113516-Administration, Inhalation,
pubmed-meshheading:9113516-Administration, Intranasal,
pubmed-meshheading:9113516-Aerosols,
pubmed-meshheading:9113516-Animals,
pubmed-meshheading:9113516-Cations,
pubmed-meshheading:9113516-Chloramphenicol O-Acetyltransferase,
pubmed-meshheading:9113516-DNA,
pubmed-meshheading:9113516-Excipients,
pubmed-meshheading:9113516-Female,
pubmed-meshheading:9113516-Gene Therapy,
pubmed-meshheading:9113516-Gene Transfer Techniques,
pubmed-meshheading:9113516-Lipid Metabolism,
pubmed-meshheading:9113516-Lung,
pubmed-meshheading:9113516-Mice,
pubmed-meshheading:9113516-Mice, Inbred BALB C,
pubmed-meshheading:9113516-Phosphatidylethanolamines,
pubmed-meshheading:9113516-Plasmids,
pubmed-meshheading:9113516-Pneumonia,
pubmed-meshheading:9113516-Polyethylene Glycols,
pubmed-meshheading:9113516-Transfection
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung.
|
|
pubmed:affiliation |
Genzyme Corporation, Framingham, MA 01701-9322, USA.
|
|
pubmed:publicationType |
Journal Article
|
